Fig. 1.

Overall survival according to a-c the presence or absence of loss of 17p among a all patients with cytogenetic information, b patients with CK+ and c patients with MK+, and overall survival according to d the presence or absence of a TP53 mutation among all patients with samples subjected to panel sequencing (corresponding COX model: HR 2.31, 95% CI 1.03–5.16, P = 0.041), e the presence or absence of minor subclones among patients with available data (corresponding COX model: HR 2.29, 95% CI 0.98–5.39, P = 0.056), and f the presence of a TP53 mutation or a minor subclone or absence of both among patients with available data (corresponding COX model: HR 2.63, 95% CI 1.20–5.79, P = 0.016)